Hims & Hers Health (HIMS) Company Report

Hims & Hers Health (HIMS) has expanded its weight-loss program to the UK via its Hers platform, providing personalized weight management plans that include access to branded GLP-1 treatments such as Wegovy and Mounjaro.
This move enhances the company's existing telehealth services and signifies an increased European footprint, building on its acquisition of Zava, which also covers Germany, France, and Ireland.
The company, with a market capitalization of approximately $9.06 billion, has seen its stock rally 65% year-to-date, largely due to high demand for GLP-1 treatments and international growth.
Hims & Hers operates on a direct-to-consumer model, not accepting insurance for its services, and faces challenges including margin pressures and market access limitations for GLP-1 drugs in the UK.

Dec 10, 2025, 9:02 AM

Morningstar

Hims & Hers launches Weight Loss Programme and Hers platform in the UK

HIMS

Product Launch

New Projects/Investments

Hims & Hers is expanding its comprehensive Weight Loss Programme to the UK, which includes the official introduction of the Hers platform for women.
The program offers eligible individuals access to doctor-designed weight management care, potentially including branded GLP-1 options such as Mounjaro or Wegovy, and the oral non-prescription treatment Orlos.
This expansion addresses the issue of 64% of UK adults being overweight or living with obesity and aims to remove barriers to accessing GLP-1 treatment plans, which are challenging to obtain through the NHS and private sector due to surging demand and escalating costs.

Dec 10, 2025, 8:30 AM

Press Release

Hims & Hers Expands into Canada and Enhances Telehealth Capabilities

HIMS

M&A

New Projects/Investments

Hims & Hers has expanded its direct-to-consumer telehealth platform into the Canadian market through the acquisition of Livewell, a digital health platform focused on weight loss.
The company acquired YourBio Health to integrate pain-free, capillary blood sampling technology, enhancing its diagnostic capabilities.
Additionally, Hims & Hers strengthened its integrated telehealth and prescription fulfillment model by acquiring peptide manufacturing and laboratory businesses, supporting a broader range of treatments including weight loss, menopause, and low-testosterone care.

Dec 3, 2025, 7:36 PM

Morningstar

Hims & Hers Health Appoints Deb Autor as Chief Policy Officer

HIMS

Management Change

Product Launch

Demand Weakening

Hims & Hers Health has appointed Deb Autor as its first Chief Policy Officer, bringing over 30 years of experience in healthcare policy and regulation, including her previous role as Deputy Commissioner for Global Regulatory Operations and Policy at the FDA.
Autor's appointment is a strategic move to lead global public policy and regulatory affairs, supporting the company's vision and expansion into new services such as health monitoring and blood testing.
The company faces challenges including increased competition in the weight-loss drug market due to price cuts by Novo Nordisk on GLP-1 drugs, which led to a 4.9% decline in Hims & Hers' stock price.

Nov 17, 2025, 11:12 AM

Morningstar

Hims & Hers Health Faces Wrongful Death Lawsuit

HIMS

Legal Proceedings

Hims & Hers Health, Inc. (Hims) is facing a wrongful death lawsuit filed this week by the parents of Luke Tyler in King County Superior Court.
The lawsuit alleges that Hims prescribed a 90-day supply of an antidepressant to Luke Tyler, who had a disclosed history of undiagnosed depression and self-harm, following an Instagram ad. The dosage was later doubled without consultation, and Luke subsequently died by suicide using the prescribed medication.
The Tylers claim Luke's death was a foreseeable consequence of Hims' expansion into mental healthcare via telehealth, alleging the company used Affiliated Medical Groups (AMGs) with unqualified medical professionals to circumvent regulations and rapidly issue prescriptions, violating Washington law.

Nov 14, 2025, 4:06 PM

Press Release

Hims & Hers Launches "Labs" Proactive Healthcare Service

HIMS

Product Launch

New Projects/Investments

Hims & Hers has launched Labs, a new service offering a proactive and accessible healthcare experience that includes blood tests, personalized health insights, and actionable treatment plans.
Labs provides two options: a base option with 50 biomarker tests and an advanced option with over 120 biomarker tests across 10 key categories, measured twice a year.
The platform leverages machine learning and AI to identify personalized treatment options and plans to expand into advanced diagnostics for chronic diseases, cancers, and genetic risk markers at a reduced cost.

Nov 13, 2025, 5:00 PM

Transcript

Hims & Hers Launches "Labs" Proactive Healthcare Service

HIMS

Product Launch

New Projects/Investments

Hims & Hers has introduced Labs, a new proactive healthcare experience designed to provide accessible and actionable health insights through comprehensive testing and personalized recommendations.
The Labs service allows users to get blood drawn for biomarker testing, receive a detailed health picture, and access treatment plans and lifestyle recommendations from independent providers via the Hims & Hers app.
Labs offers a Base option with 50 biomarker tests and an Advanced option with over 120 biomarker tests performed twice yearly, leveraging AI and machine learning for personalized treatment identification.
Hims & Hers plans future expansions for Labs to include in-home testing and advanced diagnostics for chronic diseases, various cancers, and genetic risk markers, which they intend to offer at a fraction of typical costs.

Nov 13, 2025, 5:00 PM

Transcript

Hims & Hers Launches Labs Product for Personalized Blood Test Analysis

HIMS

Product Launch

New Projects/Investments

Demand Weakening

Hims & Hers Health has launched Labs, a new product designed to provide personalized health insights derived from blood tests.
Labs offers two subscription plans: a $199 base plan for one annual blood draw covering 50 biomarkers, and a $499 advanced plan with two draws analyzing over 120 biomarkers.
The service aims to make proactive, data-driven healthcare more accessible and affordable and is part of Hims & Hers' strategy to stimulate growth amid challenges in its core sexual health and weight-loss businesses.
The company acquired Trybe Labs, an at-home blood-testing facility, in February to support this initiative.

Nov 13, 2025, 4:57 PM

Morningstar

Hims & Hers Health Reports Strong Q3 2025 Revenue Growth, Narrows FY25 EBITDA Guidance

HIMS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Hims & Hers Health reported Q3 2025 revenue of approximately $599 million, representing 49% year-over-year growth and surpassing market expectations, although the company missed GAAP EPS estimates and provided Q4 revenue guidance slightly below analyst forecasts.
The company narrowed its full-year 2025 adjusted EBITDA guidance to a range of roughly $307 million to $317 million.
While maintaining a strong gross margin near 76% and growing its subscriber base to over 2.4 million customers, operating margins declined significantly to 2% in Q3 2025 from 5.6% in the prior year, and free cash flow margin also decreased.

Nov 3, 2025, 10:15 PM

Morningstar

Hims & Hers Health Reports Strong Q3 2025 Results and Outlines Strategic Growth Initiatives

HIMS

Earnings

Guidance Update

New Projects/Investments

Hims & Hers Health reported Q3 2025 revenue of nearly $600 million, marking a 49% year-over-year increase, and achieved adjusted EBITDA of $78 million with over 13% margins.
The company provided Q4 2025 revenue guidance of $605 million to $625 million and adjusted EBITDA guidance of $55 million to $65 million. For full-year 2025, revenue is projected to be between $2.335 billion and $2.355 billion, with adjusted EBITDA between $307 million and $317 million.
Strategic developments include active discussions with Novo Nordisk to make Wegovy available, a partnership with Marius Pharmaceuticals for an FDA-approved oral testosterone treatment in 2026, and a strategic investment in GRAIL for multi-cancer early detection.
New offerings include a perimenopause and menopause solution for the Hers brand, which is expected to reach $1 billion in annual revenue in 2026, and a planned launch of comprehensive whole-body lab testing before year-end.
The company is expanding its operational footprint to over 1 million sq ft by year-end and continues international expansion, including the Zava acquisition in Europe and upcoming entry into Canada.